Member Info for Digger01

Yes, if the USA like today’s RNS, which I expect they will, then any movement “should” be reflected here. Remember that there are 8 Aim shares to every Nasdaq ADS plus the exchange rate difference.

Has anyone read any confirmation of re-commencement if mining at Immaculada, which was alluded to start last week? Thus may well be holding this back from a more aggressive advance in SP.

I have also lost a lot of money on paper, however, having suffered and believed for 11 years, one more is no problem! It’s a shame that I don’t have the conviction to trade albeit VERY predictable. Anyway, interesting times ahead.

Good point made and I agree that we have a clear path in front of us, so hopefully the SP will hold. I do NOT have medical knowledge and only comment based on the RNS history. However I noted some time ago that they seemed to change tact with the last few trials, aiming for improvement in peak FEV and general well being of the recipients, whereas previous trials have also recorded “trough” figures which didn’t seem to demonstrate the same level of improvement compared to peak. From memory over 12 years invested, every trial has demonstrated Peak improvement, so it would seem logical that they have agreed the ENHANCE program based on this as a primary end point. This certainly gives me confidence. DYOR

I hope you are right Rhodi and I agree in the longer term. However, the out licensing of DPI and MDI will probably be more likely after the part two results of the MDI which got delayed. However, I assume that those devices will require separate P3 trials, so out licensing has to be the way and as previously stipulated.

The raise was never in doubt in my mind and the message is still clear, go it alone for the Nebulised version and out license the DPI and MDI. Yes diluted, but great to see some of the II’s continue to back it, who also backed the last raise into the US listing. Maybe a condition was a new top team? The science has always been good. Forget COVID guys, COPD is a huge killer and global market. I would rather have a smaller piece of a successful cake than a dud recipe.
It’s a shame that it’s taken over 12 years of my money so far!

See the last RNS 8th July. Check “Investegate”

I am concerned with the COVID stats coming out of Mexico and indeed Latin America. HOC have had to close their flagship asset in Peru again. Hopefully this won’t happen in Mexico for Fres.

Many thanks for your feedback to my question, which makes perfect sense; much appreciated.

I have recently jumped on board here and have read a number of informative posts, which is much appreciated.
Can anyone advise if the Nuvec delivery (once proven) will require any third party approval to be able to market? Such as MHRA / FDA etc. Ie will it require to go through a lengthy testing regime? Sorry if it’s a dumb question.

I would say that the company already has some big investors who joined the club when we raised $100m + and I am sure they would have exercised due diligence. They are still substantial share holders and nothing has changed in terms of the product or trial results. So unless theee is something going on here that is not in the public domain, one would assume that they still believe in the science and would be none to keen to completely write off their investment. On this basis, I am very optimistic that we will gain the funding required, however based on the current SP, more large scale dilution. Maybe that’s the plan? These guys want a bigger chunk of the pie in order to offer the money.

Very apt comments Rhodi, almost hilarious but of course this isn’t funny, it’s a disgrace. 11 years of this and probably another 2 at least (And that’s assuming things go to the latest plan) The only thing that gives me hope, is that they always seem to get quality investors involved albeit at PI expense vial dilution. I probably need about £2.50 to break even here, but I would gladly take half of that!
We have been talking about this beer for years and I have no idea how I am still alive in this desert of VRP.
Come on BODS - prove yourselves!
If they do, let’s go for a crate!

I guess we need to wait for an official announcement either way as they may be ok based on:
He said the latest extension would come with more "flexibility", including the gradual reopening of certain sectors.
RNS last week started that they had met very stringent requirements, in order to re-open.

Huge amount of freebies again.... This is worse than Groundhog Day, but unfortunately at our expense.
I just hope that these guys can make a difference and NOT jam tomorrow as usual.

I agree Wudi, the actual raising of funds by one means or another, will not likely be an issue. However the wording of the RNS to me indicates that equity will likely be heavily diluted. We will see. GLA

They have clearly stated that they need to raise funds and that it would not be easy.” The Company is continuing to evaluate available sources of capital, however, the cost and other terms of such capital have become more onerous as a result of the impacts of the COVID-19 pandemic on the financial markets” When they raised the previous substantial funds from primary Pharma investors, David Ebsworth said that the due diligence was intensive, so we assume that they had faith in the compound and the management at the time. In terms of the trials, they have all been a success bar one add on. So in terms of the planned road trip to commercialisation, nothing has changed bar the new CFO , CMO, and CFO, the true reasons for which, remain unknown. So I would suggest a heavy dilution OR a partnership of some description, however, the latter would probably deminish any potential longer term shareholder gains.

Good predictions Fuhrer, and as I also said, nothing new, at least in the announcement. I will listen in today, but I see no reason why any news beyond the RNS should be forthcoming. Expected but still disappointing. I guess it’s a case of how much dilution will be forced upon us, but in this environment, it’s probably going to be a giveaway.
The only thing not mentioned, is the commercialisation strategy of the inhaler versions, which could assist funding.
However, I would suggest that the real value if this would be better realised post any P3 success of the Nebulised version. Looks like another two years of waiting.!!

Rhodi, since the last operational update on the 27th Feb we have had part 1 MDI trial update, but other than that, what new information could we possibly expect on Thursday?
Maybe a date has been agreed with the FDA for the pre-P3 trials, but Other than this, it would be something new.
Am I missing anything?

Does anyone have any idea approximately when an FDA update is expected? I can’t seem to find anything in the RNS history?

Hi Izstsr and Rhodi, glad you guys are ok and hopefully well at this difficult time. My wife and myself are fine and our house and gardens are immaculate!!
I still think that we have a product to take to market and it seems like we have a team in place to make it happen.
Although we wait for part two of the MDI trial, I firmly believe that the outcome will be similar to that of DPI. These products are to be partnered / out licensed, so I guess a deal could be done at any time, and IF sooner rather than later, this may help to fund P3 for the Nebulised version. I guess that VRP are still looking to go alone with the Nebulised version. It’s still a risk in terms of investment, but the compound is now substantially de-risked and the CMO seems very positive and has the experience.
Hopefully no further dilution. Still I think that crunch tune is coming. GL all.